| Schedule of net loss attributable to non-controlling interest |
|
|
BioCorRx
Pharmaceuticals,
Inc.
|
|
|
Joseph
DeSanto
MD
|
|
Net loss |
|
$ |
(1,849 |
) |
|
$ |
(1,881 |
) |
Average Non-controlling interest percentage of profit/losses |
|
|
24.2 |
% |
|
|
35.0 |
% |
Net loss attributable to the non-controlling interest |
|
$ |
(448 |
) |
|
$ |
(658 |
) |
|
|
BioCorRx
Pharmaceuticals,
Inc.
|
|
Net loss |
|
$ |
(7,257 |
) |
Average Non-controlling interest percentage of profit/losses |
|
|
24.2 |
% |
Net loss attributable to the non-controlling interest |
|
$ |
(1,756 |
) |
|
|
BioCorRx
Pharmaceuticals,
Inc.
|
|
|
Joseph
DeSanto
MD
|
|
Net loss |
|
$ |
(3,296 |
) |
|
$ |
(3,550 |
) |
Average Non-controlling interest percentage of profit/losses |
|
|
24.2 |
% |
|
|
35.0 |
% |
Net loss attributable to the non-controlling interest |
|
$ |
(798 |
) |
|
$ |
(1,242 |
) |
|
|
BioCorRx
Pharmaceuticals,
Inc.
|
|
Net loss |
|
$ |
(9,533 |
) |
Average Non-controlling interest percentage of profit/losses |
|
|
24.2 |
% |
Net loss attributable to the non-controlling interest |
|
$ |
(2,307 |
) |
Balance, December 31, 2022 |
|
$ |
(125,257 |
) |
Net loss attributable to the non-controlling interest |
|
|
(2,040 |
) |
Balance, June 30, 2023 |
|
$ |
(127,297 |
) |
Balance, December 31, 2021 |
|
$ |
(117,838 |
) |
Net loss attributable to the non-controlling interest |
|
|
(2,307 |
) |
Balance, June 30, 2022 |
|
$ |
(120,145 |
) |
|